Membership: 

Amgen Inc., BASF Corporation, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Hoffmann-La Roche Inc., L’Oreal, Novartis Pharmaceuticals Corporation, The Procter & Gamble Company, sanofi-aventis, Schering-Plough Research Institute, Syngenta Ltd.

Public Participation: 

European Food Safety Authority, Georgetown University Medical Center, Imperial College London, Indiana University School of Medicine, International Agency for Research on Cancer, Michigan State University, RIVM (National Institute for Public Health and the Environment), NIEHS National Toxicology Program, Stratoxon LLC, Technical University of Munich, University of Nebraska Medical Center, University of North Carolina (Chapel Hill), US Environmental Protection Agency (National Health and Environmental Effects Research Laboratory, Office of Pesticide Programs), US Food and Drug Administration (Center for Drug Evaluation and Research, National Center for Toxicological Research)

Project Committee Goals and Activities: 

The Project Committee proposes to define a minimum data set necessary to identify a potential human cancer hazard.  In so doing, alternative strategies will be carefully assessed.  Among the Subcommittee’s anticipated deliverables are:

• a data-based assessment of alternative strategies for identification of potential human cancer hazards;
• a publicly available database which supports progress in the field;
• an open workshop at which the outcome of the Subcommittee’s assessments will be presented, available data will be reviewed, and implications and potential new directions will be discussed; and
• one or more publications in the scientific, peer-reviewed literature.